eMedicine Specialties > Hematology > Red Blood Cells and Disorders

Spherocytosis, Hereditary: Follow-up

Author: Gus Gonzalez, MD, Medical Oncologist, The Center for Cancer and Blood Disorders
Coauthor(s): E Randy Eichner, MD, Professor, Department of Internal Medicine, University of Oklahoma Health Sciences Center
Contributor Information and Disclosures

Updated: Aug 27, 2009

Follow-up

Further Inpatient Care

  • Evaluation for splenectomy by a surgeon should take place. Consideration of a partial splenectomy can be sought if access to a surgeon experienced in this procedure is possible.

Further Outpatient Care

  • After splenectomy, RBC survival improves dramatically, enabling most patients with HS to maintain a normal hemoglobin level.
  • Ideally, splenectomy should not be performed until a child is older than 6 years because of the increased incidence of postsplenectomy infections with encapsulated organisms such as S pneumoniae and H influenzae in young children.

Inpatient & Outpatient Medications

  • Lifelong folic acid supplementation is recommended for these patients secondary to low levels of chronic hemolysis. This is especially true for those who have not undergone splenectomy.

Complications

  • Often, the patient has had multiple RBC transfusions. This occurs because of multiple hemolytic episodes or an inaccurate diagnosis. Iron overload can become a serious problem, resulting in liver dysfunction. Another cause of iron overload is the addition of oral iron supplementation for the anemia. If a patient presents with mild liver dysfunction, iron store studies should be performed.

Prognosis

  • After splenectomy, RBC survival improves dramatically, enabling most patients with HS to maintain a normal hemoglobin level.

Miscellaneous

Medicolegal Pitfalls

  • Occasionally, patients with HS are incorrectly diagnosed with Gilbert disease.
  • Vaccination against pneumococcal organisms and H influenzae must be administered to patients prior to splenectomy and, indeed, probably to all patients with severe HS.
  • If a partial splenectomy is performed, splenic function is preserved and vaccinations may be delayed until after surgery; however, the long-term data is not well established.

Special Concerns

  • After splenectomy, all patients should have yearly immunizations updated as needed, especially those covering encapsulated organisms.
  • All patients should be placed on supplemental folic acid replacement because of chronic hemolysis.
 


More on Spherocytosis, Hereditary

Overview: Spherocytosis, Hereditary
Differential Diagnoses & Workup: Spherocytosis, Hereditary
Treatment & Medication: Spherocytosis, Hereditary
Follow-up: Spherocytosis, Hereditary
References
Further Reading

References

  1. Perrotta S, Della Ragione F, Rossi F, et al. {beta}-spectrinBari: a truncated {beta}-chain responsible for dominant hereditary spherocytosis. Haematologica. Jul 16 2009;epub ahead of print. [Medline][Full Text].

  2. Maciag M, Plochocka D, Adamowicz-Salach A, Burzynska B. Novel beta-spectrin mutations in hereditary spherocytosis associated with decreased levels of mRNA. Br J Haematol. Aug 2009;146(3):326-32. [Medline].

  3. Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet. Oct 18 2008;372(9647):1411-26. [Medline].

  4. Abdullah F, Zhang Y, Camp M, Rossberg MI, Bathurst MA, Colombani PM, et al. Splenectomy in hereditary spherocytosis: Review of 1,657 patients and application of the pediatric quality indicators. Pediatr Blood Cancer. Jul 2009;52(7):834-7. [Medline].

  5. Morinis J, Dutta S, Blanchette V, Butchart S, Langer JC. Laparoscopic partial vs total splenectomy in children with hereditary spherocytosis. J Pediatr Surg. Sep 2008;43(9):1649-52. [Medline].

  6. Grace RF, Mednick RE, Neufeld EJ. Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. Pediatr Blood Cancer. Jul 2009;52(7):865-7. [Medline].

  7. Agre P, Asimos A, Casella JF, McMillan C. Inheritance pattern and clinical response to splenectomy as a reflection of erythrocyte spectrin deficiency in hereditary spherocytosis. N Engl J Med. Dec 18 1986;315(25):1579-83. [Medline].

  8. Costa FF, Agre P, Watkins PC, et al. Linkage of dominant hereditary spherocytosis to the gene for the erythrocyte membrane-skeleton protein ankyrin. N Engl J Med. Oct 11 1990;323(15):1046-50. [Medline].

  9. Gallagher PG. Hematologically important mutations: ankyrin variants in hereditary spherocytosis. Blood Cells Mol Dis. Nov-Dec 2005;35(3):345-7.

  10. Glader BE, Naumovski L. Hereditary red blood cell disorders. In: Emery AE, Rimoin, DL, eds. Principles and Practice of Medical Genetics. New York, NY:. Churchill Livingstone;1996.

  11. Hassoun H, Palek J. Hereditary spherocytosis: a review of the clinical and molecular aspects of the disease. Blood Rev. Sep 1996;10(3):129-47. [Medline].

  12. Hassoun H, Vassiliadis JN, Murray J, et al. Hereditary spherocytosis with spectrin deficiency due to an unstable truncated beta spectrin. Blood. Mar 15 1996;87(6):2538-45. [Medline].

  13. Korones D, Pearson HA. Normal erythrocyte osmotic fragility in hereditary spherocytosis. J Pediatr. Feb 1989;114(2):264-6. [Medline].

  14. Lee RD, Glader JN, Lukens JN. In: Lee GR, Foerster J, Lukens J, Paraskevas F, Greer JP, Rodgers GM, eds. Wintrobe's Clinical Hematology. 10th ed. Baltimore, Md: Lippincott Williams & Wilkins; 1999:. 1132-42.

  15. Nakashima K, Beutler E. Erythrocyte cellular and membrane deformability in hereditary spherocytosis. Blood. Mar 1979;53(3):481-5. [Medline].

  16. Peters LL, Lux SE. Ankyrins: structure and function in normal cells and hereditary spherocytes. Semin Hematol. Apr 1993;30(2):85-118. [Medline].

  17. Rice HE, Oldham KT, Hillery CA, et al. Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. Ann Surg. Feb 2003;237(2):281-8.

  18. Sackey K. Hemolytic anemia: Part 1. Pediatr Rev. May 1999;20(5):152-8; quiz 159. [Medline].

  19. Sackey K. Hemolytic anemia: Part 2. Pediatr Rev. Jun 1999;20(6):204-8. [Medline].

  20. Savvides P, Shalev O, John KM, Lux SE. Combined spectrin and ankyrin deficiency is common in autosomal dominant hereditary spherocytosis. Blood. Nov 15 1993;82(10):2953-60. [Medline].

  21. Stoehr GA, Stauffer UG, Eber SW. Near-total splenectomy: a new technique for the management of hereditary spherocytosis. Ann Surg. Jan 2005;241(1):40-7.

Further Reading

Related eMedicine Topics

Clinical Trials

National Guideline Clearinghouse

Keywords

hereditary spherocytosis, HS, congenital spherocytosis, familial hemolytic disorder, hemolytic anemia, anemia, blood disorder, hereditary hemolytic anemia, aplastic crisis, megaloblastic crisis, hemolytic crisis, cholecystitis, cholelithiasis, neonatal hemolysis, splenomegaly

Contributor Information and Disclosures

Author

Gus Gonzalez, MD, Medical Oncologist, The Center for Cancer and Blood Disorders
Gus Gonzalez, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine
Disclosure: Nothing to disclose.

Coauthor(s)

E Randy Eichner, MD, Professor, Department of Internal Medicine, University of Oklahoma Health Sciences Center
E Randy Eichner, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Sports Medicine, American Medical Society for Sports Medicine, and American Society of Hematology
Disclosure: Nothing to disclose.

Medical Editor

Paul Schick, MD, Emeritus Professor, Department of Internal Medicine, Thomas Jefferson University Medical College; Research Professor, Department of Internal Medicine, Drexel University College of Medicine; Adjunct Professor of Medicine, Lankenau Hospital, Wynnewood, PA
Paul Schick, MD is a member of the following medical societies: American College of Physicians, American Heart Association, American Society of Hematology, International Society on Thrombosis and Haemostasis, and New York Academy of Sciences
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Ronald A Sacher, MB, BCh, MD, FRCPC, Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center
Ronald A Sacher, MB, BCh, MD, FRCPC is a member of the following medical societies: American Society of Hematology
Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; Talecris Honoraria Board membership

CME Editor

Rajalaxmi McKenna, MD, FACP, Consulting Staff, Department of Medicine, Southwest Medical Consultants, SC, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University
Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, and New York Academy of Sciences
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.